30th May 2025

Genedrive® CYP2C19 ID Kit receives CE-certification under the European In Vitro Diagnostics Regulation

genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, announces the succ...

13th May 2025

Genedrive® CYP2C19-ID Kit to be used to support expansion of use to include Acute Coronary Syndrome

genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, is pleased to anno...

2nd Apr 2025

Genedrive awarded additional grant funding under the DEVOTE programme

genedrive plc (AIM:GDR), the point of care pharmacogenetic testing company, is pleased to annou...